VEGFA and breast cancer: Kil et al. reported that silibinin (50 μg/mL) could inhibit metastasis and migration by inhibiting EGFR phosphorylation and suppressing VEGF, MMP‐9, and COX‐2 in MDA‐MB‐468 cells, resulting in decreased tumor volume in the triple‐negative BC xenograft model.136